- CASGEVY Q3 revenue was $99 million, up 30% QoQ and ~6x year-over-year with >750 patients treated.
- Q3 net loss widened slightly to $111.4 million compared to $106.4 million in Q3 2025; GAAP EPS reported at $(1.15).
- G&A expenses held stable at $17.9 million versus $16.9 million in the prior-year period.
Signal #104549 · SEC 8-K
$CRSP SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $CRSP filing catalyst
Why did $CRSP trigger an AI stock catalyst alert?
$CRSP triggered a Stock Catalyst AI alert on 2026-11-02 00:00:00 UTC for a SEC 8-K filing (AI Score: +3.0/10). Headline: CRISPR Therapeutics Reports Q3: CASGEVY Sales Reach $99M (+30% QoQ), Net Loss $111.4M. Key points: - CASGEVY Q3 revenue was $99 million, up 30% QoQ and ~6x year-over-year with >750 patients treated. - Q3 net loss widened slightly to $111.4 million compared to $106.4 million in Q3 2025; GAAP EPS reported at $(1.15). - G&A expenses held stable at $17.9 million versus $16.9 million in the prior-year period.
How did $CRSP stock react after the SEC filing?
After the SEC 8-K for $CRSP, observed market reaction: T0 price $49.99. Past moves do not guarantee future results.
Where can I get real-time $CRSP SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $CRSP via Telegram and the VIP Web Terminal from €10/month.